Skip to content

Sarepta Therapeutics announce start of clinical trial for LGMD2E/R4

24 January 2024

Sarepta Therapeutics have started screening for a new clinical trial to investigate a gene therapy for limb girdle muscular dystrophy 2E/R4, which can be delivered into muscle tissues including the heart. This will initially start in the US.

Limb girdle muscular dystrophy 2E/R4, also known as beta sarcoglyanopathy, is a progressive genetic condition caused by changes in the protein called beta-sarcoglycan. It affects the muscles around the hips and shoulders before progressing to the leg and arm muscles. There are currently no treatments for this condition.

Sarepta Therapeutics have begun screening − matching potential participants with their eligibility criteria − for a clinical trial to investigate a gene therapy, SRP-9003, to treat LGMD2E/R4. SRP-9003 is an investigational gene therapy, which can be delivered into muscle tissue, including the heart. This is very important for people living with LGMD2E/R4, as the condition affects their heart muscle. The therapy is intended to deliver full-length beta-sarcoglycan into the cells of people living with LGMD2E/R4.

The trial, called EMERGENE, is a phase III, open-label, multi-national clinical trial. It will recruit 15 participants aged four or over; those who can walk and those who use a wheelchair. Recruitment will start at the US sites first − we’ll provide an update about potential UK/European sites when this information becomes available.

Read Sarepta Therapeutics’ press release in full here.

Stay connected with our community

Get the latest news, inspiring stories, upcoming events, and valuable support services delivered straight to your inbox.